118 related articles for article (PubMed ID: 38367405)
1. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
[TBL] [Abstract][Full Text] [Related]
2. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
Saal J; Bald T; Eckstein M; Ralser DJ; Ritter M; Brossart P; Grünwald V; Hölzel M; Ellinger J; Klümper N
JAMA Oncol; 2023 Aug; 9(8):1048-1055. PubMed ID: 37347489
[TBL] [Abstract][Full Text] [Related]
3. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
Saal J; Grünwald V; Bald T; Ritter M; Brossart P; Tomita Y; Hartmann A; Hölzel M; Eckstein M; Klümper N
Eur Urol Oncol; 2024 Jun; 7(3):328-331. PubMed ID: 37996277
[TBL] [Abstract][Full Text] [Related]
4. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
5. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Zhang Y; Chen S; Chen H; Li W
Cancer Med; 2023 Jan; 12(1):38-48. PubMed ID: 35702873
[TBL] [Abstract][Full Text] [Related]
8. Sixth-Week Immune-Nutritional-Inflammatory Biomarkers: Can They Predict Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
Olgun P; Diker O
Curr Oncol; 2023 Dec; 30(12):10539-10549. PubMed ID: 38132403
[TBL] [Abstract][Full Text] [Related]
9. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
Lung Cancer (Auckl); 2017; 8():249-257. PubMed ID: 29263709
[TBL] [Abstract][Full Text] [Related]
13. Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder.
Schuettfort VM; Gust K; D'Andrea D; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Abufaraj M; Karakiewicz PI; Luzzago S; Rouprêt M; Enikeev D; Zimmermann K; Deuker M; Moschini M; Sari Motlagh R; Grossmann NC; Katayama S; Pradere B; Shariat SF
Minerva Urol Nephrol; 2022 Jun; 74(3):302-312. PubMed ID: 34114784
[TBL] [Abstract][Full Text] [Related]
14. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Matsubara T; Takamori S; Haratake N; Toyozawa R; Miura N; Shimokawa M; Yamaguchi M; Seto T; Takenoyama M
J Thorac Dis; 2020 Apr; 12(4):1520-1528. PubMed ID: 32395289
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.
Qi F; Xu Y; Zheng Y; Li X; Gao Y
Ann Transl Med; 2019 Oct; 7(20):531. PubMed ID: 31807513
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis.
Yang C; Ren G; Yang Q
Front Surg; 2022; 9():1094973. PubMed ID: 36700011
[TBL] [Abstract][Full Text] [Related]
20. Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials.
Zhou JG; Wong AH; Wang H; Jin SH; Tan F; Chen YZ; He SS; Shen G; Frey B; Fietkau R; Hecht M; Carr SR; Wang R; Shen B; Schrump DS; Ma H; Gaipl US
Front Immunol; 2022; 13():961926. PubMed ID: 36119066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
